Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creatine for Depression in Female Methamphetamine Users
NCT01514630Phase 4Completed
- Start
- Jan 2013
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of creatine in major depressive disorder (MDD). Primary endpoint: Hamilton Depression Rating Scale at 8 weeks. Started Jan 2013; status: completed.
02
Drugs
creatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01514630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01514630.